IGHE and Increased total eosinophil count: Accordingly, we recommend aligning the choice of biologic with (1) the dominant clinical goals (e.g., olfaction vs. polyp size vs. OCS/surgery reduction), (2) biologic plausibility/endotype (e.g., eosinophilia, IgE level, comorbid asthma), (3) safety/tolerability and dosing cadence, and (4) access and patient preference, recognizing that several agents can be effective and that switching may be appropriate when goals are unmet.